Recombinant Mouse SLAMF7 protein, Mouse IgG2a Fc-tagged, low endotoxin
Cat.No. : | SLAMF7-352M |
Product Overview : | Recombinant Mouse SLAMF7 protein (Ala22-Gly224)(low endotoxin), fused to Mouse IgG2a Fc tag at C-terminus, was expressed in human 293 cells (HEK293). |
- Specification
- Gene Information
- Related Products
- Download
Description : | SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation. |
Source : | HEK293 |
Species : | Mouse |
Tag : | mIgG2a |
Form : | Lyophilized from 0.22 um filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5, 10% trehalose. |
Molecular Mass : | The protein has a calculated MW of 49.4 kDa. The protein migrates as 55-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | 203 |
Endotoxin : | Less than 0.1 EU per ug by the LAL method. |
Purity : | >95% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 centigrade to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | SLAMF7 |
Official Symbol : | SLAMF7 |
Synonyms : | SLAMF7; SLAM family member 7; novel Ly9; leukocyte cell-surface antigen; 19A; CS1; 19A24; CRACC; 4930560D03Rik |
Gene ID : | 75345 |
mRNA Refseq : | NM_144539 |
Protein Refseq : | NP_653122 |
UniProt ID : | Q8BHK6 |
Products Types
◆ Recombinant Protein | ||
SLAMF7-448H | Recombinant Full Length Human SLAMF7 Protein, His-tagged | +Inquiry |
SLAMF7-2328H | Recombinant Human SLAMF7 protein(Met1-Met226), hFc-tagged, Biotinylated | +Inquiry |
Slamf7-5898M | Recombinant Mouse Slamf7 Protein, Myc/DDK-tagged | +Inquiry |
SLAMF7-0692H | Recombinant Human SLAMF7 protein, hFc-tagged | +Inquiry |
SLAMF7-294H | Recombinant Human SLAMF7 Protein (ECD), Fc-His-tagged(C-ter) | +Inquiry |
◆ Lysates | ||
SLAMF7-2378HCL | Recombinant Human SLAMF7 cell lysate | +Inquiry |
SLAMF7-2591MCL | Recombinant Mouse SLAMF7 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIt has a high solubility and can be easily prepared at the desired concentration.
It was found to be well active and could effectively perform the required biological activity experiments.
It was observed that SLAMF7 had good crystallinity, which was conducive to crystallography research.
Q&As (6)
Ask a questionSLAMF7 protein is involved in regulating immune cell activation, proliferation, and transmission of background signals by binding to activating ligands, such as CD319, thereby influencing the immune response.
By combining with immunotherapy, such as anti-PD-1 antibodies, the immune response can be further enhanced and the anti-tumor effect can be improved. The study of SLAMF7 protein provides a new direction for the development of combinatorial therapeutic strategies.
This protein is mainly expressed in the immune system, including immune cells such as plasma cells, NK cells, and activated T cells.
The role of SLAMF7 protein in other types of cancer is unclear, and further research is needed to determine its potential role in other cancers.
Yes, the SLAMF7 protein has been shown to be a potential therapeutic target. A monoclonal antibody drug targeting SLAMF7 protein (Elotuzumab) has been developed for the treatment of multiple myeloma.
SLAMF7 protein interacts with NK cells in multiple myeloma and plays a role in inhibiting and controlling tumor growth by activating the anti-tumor activity of NK cells.
Ask a Question for All SLAMF7 Products
Required fields are marked with *
My Review for All SLAMF7 Products
Required fields are marked with *
Inquiry Basket